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RESULTS 
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Abstract 	  
Non-invasive prenatal testing (NIPT) uses cell-free fetal DNA to assess for fetal aneuploidy 
during pregnancy. NIPT has higher detection rates and positive predictive values than 
previous methods; however, NIPT is not diagnostic. Studies suggest patients may 
underestimate the limitations of prenatal screening. Therefore, we conducted a prospective 
cross-sectional study of ninety-four women from genetic counseling clinics in Houston, 
Texas to assess patient understanding of the residual risk for aneuploidy after receiving a 
negative NIPT. The majority of participants (66%) understood the residual risk for Down 
syndrome following negative NIPT; however, 34% of participants indicated that negative 
NIPT completely eliminated the risk. Individuals with at least four years of college education 
were more likely to understand that NIPT does not eliminate the chance of trisomy 13/18 
(p=0.012) and sex chromosome abnormality (p=0.039), and were more likely to understand 
which conditions NIPT tests for (p=0.021), compared to women with less formal education. 
These data demonstrate that despite the recent implementation of NIPT into obstetric 
practice, the majority of women are aware of its limitations after genetic counseling. 
However, clinicians may need to consider alternative ways to communicate the limitations of 
NIPT to those women with less formal education to ensure understanding. 
 
	   v	  
TABLE OF CONTENTS Approval	  Page	  ......................................................................................................................................................	  i	  Title	  Page	  ...............................................................................................................................................................	  ii	  
ACKNOWLEDGEMENTS	  ...........................................................................................................................	  iii	  
Abstract	  ..................................................................................................................................................................	  iv	  
LIST OF FIGURES	  ...........................................................................................................................................	  vi	  
LIST OF TABLES	  ...........................................................................................................................................	  vii	  Introduction	  .........................................................................................................................................................	  1	  
Methods	  ..................................................................................................................................................................	  2	  
Results	  .....................................................................................................................................................................	  3	  
Figure 1: Survey Completion Flow Diagram	  ........................................................................................	  3	  
Patient Perception of Residual Risk Post- Negative NIPT Results	  ...............................................	  5	  
Most Important and Least Important Reasons for Pursuing NIPT	  ................................................	  6	  
Patient Perception of Conditions Tested by NIPT	  ..............................................................................	  7	  
Worry Levels Before and After Negative NIPT	  ..................................................................................	  8	  
Discussion	  ..............................................................................................................................................................	  9	  
Conclusions and future directions	  .........................................................................................................	  12	  
Limitations	  .....................................................................................................................................................	  13	  
References	  ..........................................................................................................................................................	  14	  
Appendix A	  ........................................................................................................................................................	  16	  
Appendix B	  ........................................................................................................................................................	  18	  
Vita	  ........................................................................................................................................................................	  22	  
 
	   vi	  
LIST OF FIGURES 
 
Figure 1: Survey Completion Flow Diagram…………………….…………………..….….…3 
Figure 2: Patient Perception of Conditions Tested by NIPT……………………………….....8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   vii	  
LIST OF TABLES 
 
Table 1: Demographic Characteristics of Study Participants ..………………..….….……….4 
Table 2:  Patient Perception of Risk Post Negative NIPT …………………..………….….…6 
Table 3:  Most and Least Important Reasons for Pursuing NIPT………......…….....…….…..7 
Table 4: Worry Levels Before and After Negative NIPT …………………………………….9 
 
 
 
 
	   1	  
Introduction 
Chromosomal aneuploidy is estimated to occur in 1/160 live births, the vast majority 
consisting of trisomy 21, trisomy 18, trisomy 13, and sex chromosome conditions (Driscoll et 
al., 2009). Before the advent of recent prenatal testing options, women seeking information 
about aneuploidy in their pregnancy generally had two options: invasive diagnostic testing 
that confers a risk for miscarriage or non-invasive screening, which generally had false 
positive rates of 5% or more and positive predictive values between 1 and 10% (Wapner, 
2003; BJOG, 2005).  
In November 2011, Non-Invasive Prenatal Testing (NIPT), or prenatal cell free fetal 
DNA screening, became clinically available for use in high-risk populations. NIPT was 
validated in a high-risk population in multiple studies, all of which have shown similar 
accuracies for aneuploidy detection (Palomaki, 2011, 2012; Bianchi, 2012; Gil, 2013). The 
most recent meta analysis by Gil et al. in 2015 analyzed data from 37 relevant studies and 
determined that NIPT detection rates for the most common aneuploidies are approximately 
99.2% for trisomy 21, 96.3% for trisomy 18, 91% for trisomy 13 and 90-93% for sex 
chromosome aneuploidy. While the detection rates and positive predictive values (PPVs) for 
NIPT are increased in comparison to other methods of prenatal screening, NIPT is not a 
diagnostic test, and a negative NIPT result does not guarantee a pregnancy is unaffected 
(Neufeld-Kaiser et al. 2015). NIPT laboratories' marketing efforts and website content often 
focus on the detection rate rather than positive predictive value or residual risk (Mercer et al. 
2014). It is unclear whether the general patient population understands this distinction, which 
may have implications for downstream uptake of invasive testing and emotional preparation 
at birth (Tiller, 2015; Hall, 2000). Therefore, we conducted a prospective cohort study to 
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assess patient understanding of the residual risk for trisomy 21, trisomy 18, trisomy 13 and 
sex chromosome aneuploidy after receiving a negative NIPT result.  
Methods 
From August 1, 2015 through January 29, 2016, women who were at least 18 years 
old, English or Spanish speaking, and had been consented for NIPT during their genetic 
counseling appointment were invited to participate in the study.  Participating centers were 
staffed by University of Texas Health and Baylor College of Medicine prenatal genetic 
counselors in the Houston, Texas area and approved by the Institutional Review Boards: the 
University of Texas Health and Memorial Hermann Hospital (HSC-MS-15-0444), Baylor 
College of Medicine and affiliated Texas Children’s Hospital (H-37683) and the Harris 
Health System (15-09-1193). Those patients willing to take part signed a consent form 
agreeing to be contacted after their NIPT results were available (Appendix A), and only those 
with a negative result were contacted to participate. The survey consisted of a section 
designed to assess patient understanding of the limitations of NIPT, a section to assess worry 
level for various conditions, a section regarding subsequent testing, and a section with 
demographic information (Appendix B). An online survey tool, Redcap, was used to securely 
administer the survey via email and collect the data. Those participants unable to complete 
the survey via email were called and given the survey over the telephone.  Data from 
telephone calls were manually added to the Redcap data set. Data were analyzed using 
STATA, (v.14.1, College Station TX). Comparison of data between groups was evaluated 
using Chi-square analysis, Fisher exact test, Wilcoxon signed-rank test or Mann Whitney test 
where appropriate. Statistical significance was assumed at a Type I error rate of 5%. 
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Results 
 A total of 231 women agreed to participate in the study and be contacted for the 
survey. Six women were excluded either due to a positive NIPT result (n=3) or failure to 
follow-through with the blood draw (n=3). Two hundred twenty-five women were contacted 
after their negative NIPT result and asked to participate in the survey either through email or 
phone call. Twenty-nine women (13%) declined to participate after being contacted and 102 
women (45%) were never successfully contacted, leaving a total of 94 participants (42%) 
from the original 225 consented. Twelve (13%) of the surveys were incomplete, the majority 
of which were missing the last several questions of the survey (Figure 1). 
Figure 1: Survey Completion Flow Diagram 
 
The majority of participants (59%, n=55) were referred to genetic counseling due to 
advanced maternal age and most identified as non-Hispanic White (36%, n=34) or Hispanic 
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(29%, n=27). The majority of participants (64%, n=60) reported having at least a four-year 
college degree (Table 1).   
Table 1: Participant Demographics (n=94) 
Participant Demographics 
      
  Ethnicity  n % 
Non Hispanic White 34 36 
Hispanic 27 29 
Afr. American 16 17 
Asian 11 12 
Other 5 5 
No Answer 1 1 
   Household Income n  % 
Less than $25,000 10 11 
$25,000 to $49,999 15 16 
$50,000 to $74,999 16 17 
$75,000 to $99,999 15 16 
$100,000 to $149,999 20 21 
$150,000 or more 12 13 
Do not wish to answer 6 6 
   Education n % 
Some high school 1 1 
High school/GED 11 12 
Some college 22 23 
4-year degree 32 34 
Graduate degree 28 30 
   Marital Status n % 
Married/living with partner 84 89 
Unmarried 9 11 
Do not wish to answer 1 1 
   Age n % 
21-29 years 15 16 
30-34 years 15 16 
35-39 years 54 57 
40-43 years 10 11 
   Indication n % 
Advanced Maternal Age 55 59 
Positive Serum Screen 11 12 
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Ultrasound Abnormality 11 12 
Low Risk 9 10 
Two or More Indications 8 9 
 
Patient Perception of Residual Risk Post- Negative NIPT Results 
Participants were about their residual risk for Down syndrome, trisomy 13/18, sex 
chromosome aneuploidy, and any other genetic syndromes after a negative NIPT result. The 
majority of participants indicated their risk was decreased but not eliminated. Sixty-one 
percent (n=57) of women indicated their risk to have a baby with Down syndrome was much 
lower, 55% (n=52) indicated that their risk was much lower for trisomy 13/18 and 49% 
(n=46) said that their risk to have a baby with a sex chromosome aneuploidy was much 
lower.  A proportion of women also indicated that there was no residual risk after a negative 
NIPT. Specifically, 34-39% of participants indicated there was no longer a chance for their 
baby to have Down syndrome, trisomy 13/18 or a sex chromosome aneuploidy after 
receiving a negative NIPT result. Additionally, participants were asked to indicate their risk 
to have a baby with a genetic condition other than Down syndrome, trisomy 13/18 or sex 
chromosome aneuploidy after receiving a negative NIPT result. Thirteen percent (n=12) 
correctly answered that their risk was not lower than before, 29% (n=27) indicated that there 
was no longer any chance for their baby to have any genetic problem, 49% (n=46) answered 
that it was much lower than before and 9% (n=8) responded that it was somewhat lower than 
before. Women with less than a four-year college education were significantly more likely to 
incorrectly respond that there was no longer a risk for their baby to have trisomy 13/18 (p= 
0.012) or a sex chromosome abnormality (p= 0.039).  Participants with less than a four-year 
education also appeared to be more likely to indicate that there was no longer a chance for 
their baby to have Down syndrome; however, this did not reach significance (p=0.086).  
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Other demographic factors did not show a significant influence on patient perception of 
negative NIPT results (Table 2). 
Table 2: Patient Perception of Risk Post Negative NIPT (n=94) 
Perception of Residual Risk Post Negative NIPT 
  
Down 
Syndrome (%) 
T13/T18 
(%) 
Sex Chromosome 
Aneuploidy, (%) 
Any Other Genetic 
Condition, (%) 
Not lower than 
before  0  1 5 13 
Somewhat 
lower than 
before 
5 10 7 10 
Much lower 
than before 61 55 49 49 
No longer a 
chance 34 34 39 29 
 Influence of Demographic Factors on Risk Perception Post Negative NIPT 
  
Down 
Syndrome T13/T18  
Sex Chromosome 
Aneuploidy 
Any Other Genetic 
Condition 
Ethnicity p=0.440 p=0.119 p=0.177 p=0.130 
Income  p=0.588 p=0.540 p=0.166 p=0.752 
Education p=0.086 p=0.012 p=0.039 p=0.159 
Age p=0.649 p=0.550 p=0.486 p=0.885 
Indication  p=0.238 p=0.082 p=0.324 p=0.700 
 
Most Important and Least Important Reasons for Pursuing NIPT 
Participants were asked to share the most important and least important reasons for 
pursuing NIPT on a scale of one to six, with one being the most important and six being the 
least important. There was no significant difference between demographics and how 
participants ranked their reasons for pursuing NIPT (ethnicity p = 0.586, income p = 0.747, 
education p = 0.212, age p =0.373, indication p = 0.123), (Table 3). 
Table 3: Most and Least Important Reasons For Pursuing NIPT  (presented as 
percentages, n=85)  
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Patient Perception of Conditions Tested by NIPT 
Participants were asked to indicate whether NIPT could test for the following: 
intellectual disability, autism, diabetes, spina bifida, cleft lip, gender and structure of the 
heart. The vast majority of participants (92%, n=86) were able to correctly identify that NIPT 
can test for gender. When looking at the remaining six items from this question, a participant 
had to indicate that NIPT did not test for the item in order to be scored as correct. Cleft lip, 
structure of heart and spina bifida were considered structural abnormalities, while intellectual 
disability, autism and diabetes were considered non-structural. Those with less formal 
education were significantly less likely to recognize what NIPT could not test for and had 
lower scores overall (p= 0.021). Fourteen percent (5/36) of women with less formal 
education correctly answered all of the questions in comparison to thirty-seven percent 
(22/60) of those women with at least four years of college. Overall, the participants were 
more likely to believe that NIPT could test for structural abnormalities (cleft lip, spina bifida 
and structure of heart) versus non-structural abnormalities (intellectual disability, autism and 
diabetes) (p< 0.0005) and women with less than a four-year degree were even more likely 
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than those with higher education to believe that that NIPT could test for both structural 
abnormalities (p= 0.024) and non-structural abnormalities (p= 0.010), (Figure 2).   
Figure 2: Patient Perception of Conditions Tested by NIPT (n=93) 
 
 
Worry Levels Before and After Negative NIPT 
Participants were asked to rank their worry level about having a child with Down 
syndrome, trisomy 13/18 and sex chromosome abnormality pre-testing via NIPT on a scale 
of one to five with one being unconcerned and five being very concerned. Similarly, women 
were asked what their level of concern was to have a baby with any genetic condition after a 
negative NIPT result. There was a significant decline when comparing the general level of 
worry before NIPT to each of the worry levels for Down syndrome (p<0.0001), trisomy13/18 
(p<0.0001), sex chromosome aneuploidy (p<0.0001) and any other genetic condition after a 
negative NIPT result (p<0.0001). Despite the fact that NIPT cannot reduce risk for all genetic 
conditions, the majority of participants (n=67, 70%) reported a decrease in worry to have a 
baby with any genetic disorder (Table 4). 
Table 4: Worry Levels Before and After Negative NIPT (%), n=94 
0% 
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20% 
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Discussion 
This study aimed to assess patient perception of the residual risk for Down syndrome, 
aneuploidy other than Down syndrome, birth defects, and other genetic conditions, after a 
negative non-invasive prenatal test.  To our knowledge this is the first study to examine 
patient understanding of the limitations of NIPT. Our data demonstrate that despite the 
relatively recent implementation of NIPT into obstetric practice, the majority of women who 
receive genetic counseling by genetic counselors are aware of its limitations. Overall, most 
participants were able to recognize that NIPT is a screening test and that it significantly 
reduces risk for those conditions it tests for, but does not eliminate the risk entirely. Of note 
for practitioners, patient comprehension of NIPT's screening ability increased significantly 
with education level. Therefore, practitioners may need to spend additional time discussing 
the implications of a screening test with patients who have less formal education.  
Similarly, many women correctly recognized that NIPT does not test for non-
structural abnormalities such as autism, intellectual disability and diabetes or structural 
abnormalities such as heart defects, cleft lip and spina bifida. Interestingly, participants were 
more likely to incorrectly respond that NIPT could evaluate for structural abnormalities 
compared to the non-structural abnormalities. It is unclear why patient comprehension 
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differed between these groups. Heart defects and cleft lip are often associated with 
aneuploidy, therefore women may have falsely assumed that a negative NIPT reduced the 
risk for non-aneuploidy associated heart defects and clefting.  In addition, many women at 
our participating centers had an ultrasound following their genetic counseling appointment.  
Thus, they may have confused reassurance for structural conditions from the ultrasound with 
reassurance from NIPT.  Furthermore, blood may be drawn to assess alpha fetal protein 
(AFP) levels and spina bifida risk at the same time as blood is drawn for NIPT, thus women 
may have falsely believed these tests are one in the same.  Additional studies may wish to 
delve into the underlying reasons behind this misunderstanding. 
This study also demonstrated that negative NIPT results significantly decreased worry 
levels of patients regarding having a baby with Down syndrome (p <0.00001), trisomy 13/18                  
(p <0.00001), and sex chromosome aneuploidy (p <0.00001). This asserts the clinical utility 
of non-invasive prenatal testing to provide appropriate reassurance for women who 
experience anxiety regarding their risk to have a baby with aneuploidy. However, this study 
also showed that women who undergo non-invasive prenatal testing are also more likely to 
experience a false decrease in worry levels for conditions not screened by NIPT, suggesting 
that negative NIPT results may provide patients with false reassurance in addition to 
appropriate reassurance for aneuploidy. It is unclear whether or not this is due to lack of 
understanding related to NIPT or general unfamiliarity with other genetic conditions. 
Although the majority of women are likely to understand the limitations of non-
invasive prenatal testing after genetic counseling, it is clear that education level plays a role 
in comprehension. Women who had less than a four-year college education were more likely 
to believe that their non-invasive prenatal testing could eliminate their risk to have a child 
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with aneuploidy. Similarly, women with more education were more likely to understand what 
conditions were included in NIPT. These data are consistent with previous studies examining 
the role of education on patient literacy and perception of prenatal screening tests. A study by 
Wong et al. in 2012 demonstrated that women with less formal education were more likely to 
perceive second trimester ultrasound as more sensitive and diagnostic in comparison to those 
women with a higher level of education. Moreover, past studies regarding patient 
understanding of prenatal maternal serum screening demonstrated that low health literacy 
and comprehension of the limitations are associated with less years of formal education 
(Goel, 1996; Cho, 2007). Women with low health literacy may also have difficulty with 
numeracy, confounding their interpretation of the sensitivity, specificity and predictive 
values of prenatal screening methods. In 2004 Gates et al. examined the role of numeracy on 
patient understanding and concluded that women with lower levels of literacy and numeracy 
have the most difficulty in accurately interpreting information about risk. The effect of 
education and health literacy on patient understanding of prenatal screening is an important 
consideration, as approximately 40% of women 25 years and older in the United States do 
not have any formal education beyond high school (US Census Data 2014). 
An additional issue that may confuse patients is the manner in which the 99% 
detection rate for NIPT is often highlighted by the media and laboratory testing materials 
rather than focusing on the individual patient’s PPV and NPV.  Without sufficient 
background knowledge, women may get the impression that the PPV and detection rates are 
both 99%. A study by Mercer et al. in 2014 examined the impact of the availability and use 
of the Internet for gathering information about non-invasive prenatal testing. Their study 
showed a lack of comprehensiveness and quality of information regarding non-invasive 
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prenatal testing obtained through Internet sources.  Moreover, many of the websites either 
failed to mention or downplayed information about the limitations and disadvantages of 
NIPT while simultaneously promoting the accuracy of the test without mentioning the 
importance of negative and positive predictive value calculations.  It is no wonder that 
women who research NIPT on the Internet may not appreciate the residual risk for 
aneuploidy, especially women without advanced formal education.   
Conclusions and future directions 
This study demonstrates that NIPT invokes similar issues as previous prenatal 
screening modalities and that providers should be cognizant of the tendency for women with 
less formal education to overinflate the power of screening to decrease or eliminate their risk 
for a baby with a genetic condition. The incorporation of non-invasive prenatal testing into 
obstetric practice has proved both exciting and overwhelming. Although it is clear that this 
new screening option can provide tremendous benefits to women worried about having a 
baby with a common aneuploidy, proper pretest genetic counseling is essential to ensure that 
patients are informed of the limitations and potential results from NIPT. There appear to be 
numerous barriers to complete patient comprehension of non-invasive prenatal testing, 
including the low numeracy and health literacy of many members of the general population 
and the potentially misleading portrayal of the limitations of NIPT on the Internet. Genetic 
counselors and obstetricians must prioritize communicating information regarding NIPT 
accurately and clearly, so that women considering it as a screening option may be adequately 
informed. When possible, attention should be paid to a patient’s education level and 
information should be tailored accordingly. The development of patient friendly decision aids 
	   13	  
that clearly state the limitations of screening and what a negative test means may assist in 
residual risk communication, informed consent, and decision making (Vlemmix et al. 2013). 
As this was a pilot study with a limited number of participants, more research is 
needed to examine patient perception of the limitations of non-invasive prenatal testing and 
how this may vary based on patient demographic and geographic factors. Additionally, future 
studies may wish to examine whether the implementation of targeted educational materials 
and decision aids augment patient understanding of NIPT, especially as the testing platforms 
are expanded to cover more chromosomal abnormalities. Furthermore, research should be 
done to assess patient perception of positive NIPT results and whether or not women who 
screen positive accurately understand the implications and limitations of the results. 
Limitations 
This study was limited by the small sample size.  The majority of women were 
referred either due to advanced maternal age or positive serum screen.  Therefore, we cannot 
confidently extrapolate to the low risk population. In addition, 64% of participants had at 
least a 4-year college degree.  Given the association of education level with understanding, a 
larger sample size might have allowed for parsing out sub-groups from women who had less 
than a four year degree into those with some college, those with a high school diploma, and 
those without a high school diploma to further stratify the finding.  Additionally, the survey 
used was carefully developed to evaluate the aims of this study; however, this assessment 
tool has not been validated in other studies. Finally, this research was limited to the greater 
Houston, Texas area, thus these results may not be generalizable to other geographical 
regions. 
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Appendix A 
 
Patient consent form 
 
INFORMED CONSENT FORM TO TAKE PART IN RESEARCH 
Title: Patient perception of residual risk post negative NIPT results 
Letter of Information 
HSC-MS-15-0444 
Primary Investigator: Claire Singletary 
  
You are invited to take part in a research study called, “Patient perception of residual risk post 
negative NIPT results”, conducted by Claire Singletary of the University of Texas Health Science 
Center at Houston.  For this research project, she will be called the Principal Investigator or PI. 
 
The purpose of this study is to evaluate patient perception of their negative NIPT results. If you 
decide to take part in the study, the total time commitment is 15 minutes.  You are invited to take part 
in this study because you have elected to proceed with non-invasive prenatal testing (NIPT).   Women 
who choose to participate will be contacted after they receive their NIPT results.  You can refuse to 
answer any questions asked or written on any forms.  Participation in this study is voluntary.   A 
decision not to take part in this study will not change the services you receive through the University 
of Texas Health Science Center at Houston.   
 
If you agree to take part in this survey, you will agree to a 15 minute survey.  
 
You may not receive any benefit from taking part in this study.  The information you provide will 
help to determine patient understanding of non-invasive prenatal testing.  There are no known risks to 
take part in this study.  The only possible risk may be breach of confidentiality.  This information 
collected in the survey responses will not contain identifying information and will be kept on a secure 
server.  You have the alternative to choose to not take part in this study and can withdraw at any time. 
 
There is no cost and you will not be paid to take part in this study.  However, upon completion of the 
survey you can choose to be entered in a drawing to win a $50 Target gift card. You will not be 
personally identified in any reports or publications that may result from this study.  Any personal 
information about you that is gathered during this study will remain confidential to every extent of the 
law.  
 
If you have any questions about this project please contact study coordinator Theresa Wittman or PI 
Claire Singletary at 713–500-5599. 
 
If you would like to be contacted to participate after you receive your NIPT results, please provide the 
following information: 
Name:  __________________________________ 
Email:  ___________________________________       Phone Number:___________________ 
Signature:  _______________________________       Date: ___________________________ 
 
If you agree to take part in the study your agreement is completion of the survey. 
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This research project has been reviewed by the Committee for the Protection of Human Subjects 
(CPHS) of the University of Texas Health Science Center at Houston (HSC-MS-15-0444)  For any 
questions about research subjects rights call CPHS at (713) 500-7943. 
For genetic counselor use only: 
 
Date:    ______________    
 
Indication:     AMA        Positive FTS Screen    Positive Quad Screen   Ultrasound 
Abnormality   Positive Family History   
Other __________________________________ 
 
Age:    ___________ 
 
G:    _____________P:  _________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   18	  
Appendix B 
 
Prenatal patient questionnaire 
 
You were seen for genetic counseling during your current pregnancy and offered to 
participate in a survey about having a blood test called non-invasive prenatal testing, or 
NIPT.  Thank you for agreeing to be contacted to discuss your feelings about NIPT. 
 
This survey should take approximately 10 minutes to complete.  Whether or not you choose 
to participate will not impact your care in any way. Your participation is greatly appreciated.  
 
Please choose the best answer for each question: 
 
1. How many years of education you have completed? 
a. Never attended high school 
b. Some high school 
c. High school/GED 
d. Some college or 2 year/associates degree 
e. 4-year degree (BA, BS) 
f. Graduate or Professional degree (MS, MBA, PhD, MD, JD) 
g. Do not wish to answer 
 
2. What is your marital status? 
a. Married/living with partner 
b. Unmarried, living with other adults 
c. Unmarried, living without other adults 
d. Do not wish to answer 
  
3. With which race/ethnicity do you most identify? 
a. White, non-Hispanic 
b. Hispanic 
c. African-American 
d. Asian/Pacific Islander 
e. Native American 
f. Other: __________________________________ 
g. Do not wish to answer 
 
4. On a scale of 1 to 5, with 1 being unconcerned and 5 being very concerned, please rate 
what your level of concern was for your baby to have any health problem before you had 
non-invasive prenatal testing (NIPT) 
1      2       3      4      5 
 
5. On a scale of 1 to 5, with 1 being unconcerned and 5 being very concerned, please rate 
what your level of concern was to have a baby with a health problem, before you had non-
invasive prenatal testing (NIPT) 
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1      2       3      4      5 
 
6. You had a negative NIPT test. What do you feel that your chances are to have a baby with 
Down syndrome after receiving this result? After receiving a negative NIPT result I feel my 
chances are… 
a. Not lower than before 
b. Somewhat lower than before  
c. Much lower than before  
d. There is no longer a chance that my baby will have Down syndrome 
 
7. On a scale of 1 to 5, with 1 being unconcerned and 5 being very concerned, please select 
what your present level of concern is to have a baby with Down syndrome after a negative 
NIPT result 
1      2       3      4      5 
 
8. What are your chances to have a baby with trisomy 18 or trisomy 13 after receiving a 
negative NIPT result? After receiving a negative NIPT result I feel my chances are… 
a. Not lower than before 
b. Somewhat lower than before  
c. Much lower than before  
d. There is no longer a chance that my baby will have trisomy 13 or trisomy 18 
 
 
9. On a scale of 1 to 5, with 1 being unconcerned and 5 being very concerned, please select 
what your present level of concern is to have a baby with a baby with trisomy 18 or trisomy 
13 after receiving a negative NIPT result 
1      2       3      4      5 
 
10. What are your chances to have a baby with a sex chromosome condition such as Turner 
syndrome or Klinefleter syndrome after receiving a normal NIPT result?  
After receiving a negative NIPT result I feel my chances are… 
a. Not lower than before 
b. Somewhat lower than before  
c. Much lower than before  
d. There is no longer a chance that my baby will have a sex chromosome condition 
 
11. On a scale of 1 to 5, with 1 being unconcerned and 5 being very concerned, please select 
what your present level of concern is to have a baby with a sex chromosome condition after a 
negative NIPT result. 
1      2       3      4      5 
 
12. What are your chances to have a baby with a genetic condition other than Down 
syndrome, trisomy 18, trisomy 13 or a sex chromosome conditions after receiving a normal 
NIPT result? After receiving a negative NIPT result I feel my chances are… 
a. Not lower than before 
b. Somewhat lower than before  
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c. Much lower than before  
d. There is no longer a chance that my baby will have any genetic condition other than 
other than Down syndrome, trisomy 18, trisomy 13 or a sex chromosome condition 
 
13. Please select your level of worry about having a baby with a genetic condition other than 
Down syndrome, trisomy 18, trisomy 13 or sex chromosome condition  
1      2       3      4      5 
 
14. Please select whether NIPT is able to specifically test for any of the following: 
 
a. Spina bifida      Yes          No             Don’t know 
b. Cleft lip      Yes          No             Don’t know 
c. Gender     Yes          No    Don’t know 
d. Structure of heart     Yes          No             Don’t know 
e. Intellectual disability     Yes          No             Don’t know 
f. Autism     Yes          No             Don’t know 
g. Diabetes     Yes          No             Don’t know 
 
15. Have you had your anatomy ultrasound (typically performed around 20 weeks of 
pregnancy)?    Yes No 
If yes, were any abnormalities found on your ultrasound? 
If yes, please describe: ______________________    
 
16. Did you have an amniocentesis procedure (needle test) or chorionic villus sampling 
(CVS) after receiving your negative NIPT results?   Yes      No 
 
17. Are you planning to have an amniocentesis procedure (needle test) or chorionic villus 
sampling (CVS)? after receiving your negative NIPT results?  Yes  No 
 
18. If yes, why did you or why will you have an amniocentesis or CVS? (check all that 
apply) 
• Concerns from my NIPT  
• Concerns on an ultrasound 
• For piece of mind 
• For greater accuracy 
• To test for other conditions 
• Other:    
 
19. If you did not or will not have an amniocentesis (needle test) or chorionic villus sampling 
(CVS), why not? (check all that apply) 
• NIPT results were reassuring enough 
• My doctor/genetic counselor said I did not need it 
• The risk of miscarriage 
• I am not worried about other conditions NIPT did not test for 
• I am not worried about Down syndrome, trisomy 18, trisomy 13 or sex chromosome 
conditions 
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• I do not like needles 
• I will continue the pregnancy regardless of a genetic condition 
• Other: ______________________    
 
20. If your NIPT testing had come back abnormal, were you planning to have an 
amniocentesis or CVS?  
Yes         No        Unsure 
 
Why or Why Not? 
 
 
21. How has having a negative NIPT test impacted your worry level about the pregnancy? 
(please check) 
a. I worry much less 
b. I worry a little less 
c. I worry about the same 
d. I worry a little more 
e. I worry a great deal more 
 
 
22. Rank from most important (1) to least important (6) the reasons behind your decision to 
pursue NIPT? 
______To determine my baby’s gender 
______To determine my baby’s chance of having Down syndrome 
______To determine my baby’s chance of having another chromosome condition, such as    
trisomy 18, trisomy 13, or a sex chromosome disorder  
______ To avoid having amniocentesis or CVS 
______ To make my doctor happy 
______ To relieve anxiety 
 
23. Please describe below any other reason not listed above that was important in your 
decision- to pursue NIPT 
 
 
24.  Please describe below any other comments or concerns you have regarding your non-
invasive prenatal testing? 
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